Curtana Pharmaceuticals Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series B
- (Upcoming)
- Latest Deal Amount
-
$6M
- Investors
-
10
Curtana Pharmaceuticals General Information
Description
Developer of targeted therapies designed to treat brain cancer. The company focuses on adding an Olig2 inhibitor to conventional options at diagnosis to treat glioblastoma in adults and pediatric medulloblastoma in children, enabling physicians to treat their patients in an enhanced manner.
Contact Information
Website
www.curtanapharma.comCorporate Office
- 10900 Stonelake Boulevard
- Building 2, Suite 100
- Austin, TX 78759
- United States
Corporate Office
- 10900 Stonelake Boulevard
- Building 2, Suite 100
- Austin, TX 78759
- United States
Curtana Pharmaceuticals Timeline
Curtana Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Later Stage VC (Series B) | $6M | Upcoming | Generating Revenue | |||
| 17. Later Stage VC | 11-Jul-2025 | Completed | Pre-Clinical Trials | |||
| 16. Later Stage VC | 23-Jan-2023 | Completed | Pre-Clinical Trials | |||
| 15. Angel (individual) | 19-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 14. Grant | 01-May-2020 | Completed | Clinical Trials - Phase 1 | |||
| 13. Angel (individual) | 22-Apr-2020 | Completed | Product Development | |||
| 12. Angel (individual) | 19-Mar-2019 | Completed | Product Development | |||
| 11. Angel (individual) | 23-Oct-2018 | Completed | Product Development | |||
| 10. Grant | 13-Sep-2017 | $300K | $3.51M | Completed | Product Development | |
| 9. Early Stage VC | 26-Jul-2017 | $550K | $3.51M | Completed | Product Development |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Curtana Pharmaceuticals Comparisons
Industry
Financing
Details
Curtana Pharmaceuticals Competitors (70)
One of Curtana Pharmaceuticals’s 70 competitors is Day One Biopharmaceuticals, a Formerly VC-backed company based in Brisbane, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Day One Biopharmaceuticals | Formerly VC-backed | Brisbane, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Lamassu | Venture Capital-Backed | Durham, NC | ||||
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| Istesso | Private Equity-Backed | London, United Kingdom |
Curtana Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Curtana Pharmaceuticals Patents
Curtana Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021333580-A1 | Combination therapies with olig2 inhibitors | Inactive | 24-Aug-2020 | ||
| AU-2021333580-A9 | Combination therapies with olig2 inhibitors | Inactive | 24-Aug-2020 | ||
| CA-3189152-A1 | Combination therapies with olig2 inhibitors | Pending | 24-Aug-2020 | ||
| EP-4199929-A1 | Combination therapies with olig2 inhibitors | Inactive | 24-Aug-2020 | ||
| EP-4199929-A4 | Combination therapies with olig2 inhibitors | Inactive | 24-Aug-2020 | A61K31/505 |
Curtana Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Curtana Pharmaceuticals Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DEFTA Partners | Venture Capital | Minority | ||
| To Life! Capital | Angel Group | Minority | ||
| National Brain Tumor Society | Not-For-Profit Venture Capital | |||
| AngelMD | Angel Group | Minority | ||
| Biosense Global | Corporation | Minority |
Curtana Pharmaceuticals FAQs
-
When was Curtana Pharmaceuticals founded?
Curtana Pharmaceuticals was founded in 2013.
-
Where is Curtana Pharmaceuticals headquartered?
Curtana Pharmaceuticals is headquartered in Austin, TX.
-
What is the size of Curtana Pharmaceuticals?
Curtana Pharmaceuticals has 9 total employees.
-
What industry is Curtana Pharmaceuticals in?
Curtana Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Curtana Pharmaceuticals a private or public company?
Curtana Pharmaceuticals is a Private company.
-
What is Curtana Pharmaceuticals’s current revenue?
The current revenue for Curtana Pharmaceuticals is .
-
How much funding has Curtana Pharmaceuticals raised over time?
Curtana Pharmaceuticals has raised $10.1M.
-
Who are Curtana Pharmaceuticals’s investors?
DEFTA Partners, To Life! Capital, National Brain Tumor Society, AngelMD, and Biosense Global are 5 of 10 investors who have invested in Curtana Pharmaceuticals.
-
Who are Curtana Pharmaceuticals’s competitors?
Day One Biopharmaceuticals, Genentech, Lamassu, Ardelyx, and Istesso are some of the 70 competitors of Curtana Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
